Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

Clinical trial NCT04539366 · SUSPENDED

Trial details

NCT number: NCT04539366
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Childhood Neuroblastoma Recurrent Childhood Osteosarcoma Recurrent Neuroblastoma Recurrent Osteosarcoma Refractory Childhood Neuroblastoma Refractory Childhood Osteosarcoma Refractory Neuroblastoma Refractory Osteosarcoma

Start date: 2022-01-25
Primary completion: 2040-12-31
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.